KR101785970B1 - Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient - Google Patents

Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient Download PDF

Info

Publication number
KR101785970B1
KR101785970B1 KR1020150172681A KR20150172681A KR101785970B1 KR 101785970 B1 KR101785970 B1 KR 101785970B1 KR 1020150172681 A KR1020150172681 A KR 1020150172681A KR 20150172681 A KR20150172681 A KR 20150172681A KR 101785970 B1 KR101785970 B1 KR 101785970B1
Authority
KR
South Korea
Prior art keywords
muscle
atrophy
oleic acid
caused
pharmaceutical composition
Prior art date
Application number
KR1020150172681A
Other languages
Korean (ko)
Other versions
KR20170066092A (en
Inventor
김택중
김한성
김선영
Original Assignee
연세대학교 원주산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 연세대학교 원주산학협력단 filed Critical 연세대학교 원주산학협력단
Priority to KR1020150172681A priority Critical patent/KR101785970B1/en
Publication of KR20170066092A publication Critical patent/KR20170066092A/en
Application granted granted Critical
Publication of KR101785970B1 publication Critical patent/KR101785970B1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/18—Lipids
    • A23V2250/186—Fatty acids
    • A23V2250/188—Oleic acid

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of muscular atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient. The oleic acid of the present invention is useful for preventing or treating muscular atrophy, The present inventive oleic acid or its pharmaceutically acceptable salt can be effectively used as an active ingredient of a composition for preventing and treating muscular atrophy.

Description

TECHNICAL FIELD The present invention relates to a pharmaceutical composition for prevention and treatment of muscle loss comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient,

The present invention relates to a composition for preventing or treating muscular atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Muscle atrophy is a disorder characterized by muscle tissue damage due to the absence of mechanical stimuli such as decreased use of muscles, destruction of muscles due to direct injury or physical factors, restoration of muscle cells due to aging, (J), and the disability of muscle use due to nerve damage (Booth FW, J Appl Physiol Respir Environ Exerc Physiol., 1982). In general, disuse atrophy occurs gradually due to the loss of muscle strength due to the disability of the muscles of the affected part and the peripheral part due to disability or accident for a long time, and myasthenia due to the disease of the muscle itself gravis, dystrophy: progressive muscular dystrophy, myotonic muscular dystrophy, duchen type, Becker type, parietal lobe, facial shoulder brachial type, inflammation occurring in the muscle itself, muscle atrophy caused by muscle- Amyotrophic lateral sclerosis (ALS): Lou Gehrig's disease, sphinobular muscular atrophy, Kennedy's disease, and the like. Spinal musculus amyotrophy: Verdunich-Hoffmann type, Kugelberg, But also in form.

Based on the quality of life and the quality of life that has been achieved today, people's interests are concentrated more on welfare and filtration than on the past, which is concentrated in food and shelter, and they are trying to lead a healthy life through exercise. In order to apply this lifestyle, free regulation and use of the vasculature should be premised, and situations in which the use of the vasculature is impossible due to abnormal muscle function result in the limitation of the range of activity of the person and the deterioration of the quality of life .

In general, the best way to prevent the onset of muscular atrophy in daily life is to prevent muscle loss through continuous use of muscles, but even if muscles can not be used regardless of their will, such as injury or disability, It is necessary to study the countermeasures to prevent muscle atrophy by stimulating muscles or preventing muscle atrophy in such cases as well.

Reactive oxygen species are highly chemically reactive groups of molecules that are highly reactive for redox reactions that attempt to exchange electrons with nearby molecules. Due to the reactivity of these active oxygen species, surrounding substances such as protein molecules or DNA in the cell lose electrons and become oxidized to exhibit mutations, failing to perform their proper functions, and failing to function properly, Death can be induced. Oxidative stress caused by reactive oxygen species is also present in muscle cells, and oxidative stress may lead to muscle cell loss and muscle atrophy. Various stressors affect not only muscle tissue damage but also various tissues in vivo, and are attracting attention as various disease factors (MCKinnell IW., And Rudnicki MA., Cell, 2004).

When the cells are no longer viable due to stress stimuli and are dead, the progression is due to apoptosis, in which the cells are disintegrated by genetic information, and when the cells are expanded and released, There is necrosis to be removed. When the cells die by oxidative stress, apoptosis proceeds, and the DNA in the nucleus is cut into several pieces during the cell death process. DAPI staining, one of the experimental methods to confirm the degree of apoptosis, is a method of detecting adenine, thymine, guanine, and adenine (cytosine) And thymine base pairs. When DNA is cut into several pieces and adenine and thymine base pairs are exposed to the outside, DAPI, which is a fluorescent substance, can bind to DNA more. When DAPI bound to DNA is irradiated with ultraviolet rays of 300 to 400 nm, And the degree of binding of DAPI to DNA can be confirmed. This can be used to determine the extent of DNA degradation and the extent of cell death.

Oleic acid is represented by C 17 H 33 COOH in the molecular formula and UPAC name (9Z) -Octadec-9-enoic acid. The saturated fatty acid and unsaturated fatty acid according to the type of fatty acid constituting the triglyceride Unsaturated fatty acids are classified into monounsaturated fatty acids and polyunsaturated fatty acids depending on the number of carbon double bonds. Oleic acid belongs to monounsaturated fatty acids having only one double bond between carbon atoms. It is a fatty acid that is widely found in plants and animals, which is contained in vegetable oils such as olive oil and canola oil, as well as in the maintenance of animals such as cows and pigs. It is almost insoluble in water but dissolves in ethanol, benzene and chloroform. (Hostmark & Haug, 2013; Lopez-Huertas, 2010; Mesa Garcia, Aguilera Garcia, & Gil Hernandez, 2010), which is particularly beneficial to patients with hyperlipidemia and low in serum cholesterol and low in HDL cholesterol 2006; Teres et al., 2008; Yamaki et al., 2005). It is known that oleic acid contained in plants is antimicrobially effective when stored in subcutaneous fat or liver by forming glycerin and esters in animals. In addition, oleic acid contained in camellia oil has antioxidative effects. However, research has not been conducted on the effect of inhibiting muscle atrophy through antioxidant activity on muscles.

On the other hand, Korean Patent No. 1560799 discloses a composition for treating spinal muscular atrophy comprising, as an active ingredient, hnRNP M (Heterogeneous nuclear ribonucleoprotein M) or a polynucleotide encoding the hnRNP M, Patent No. 1,468,123 has a disease, amyotrophic for improving or therapeutic composition comprising a mammalian umbilical cord-derived stem cells as an active ingredient is disclosed, Korea Patent registration No. 1385191 discloses a chicory (Cichorium intybus ) extract as an active ingredient, and Korean Patent No. 1349361 discloses a pharmaceutical composition for prevention and treatment of muscle atrophy comprising Eupatorium There is chinensis . simplicifolium extract as an active ingredient. However, the effect on the muscle atrophy of oleic acid is not known at all.

Accordingly, the present inventors have made efforts to develop a novel therapeutic agent for muscular dystrophy, which is free from cytotoxicity and secured to human body. As a result, it has been found that oleic acid derived from natural materials is a natural material-derived material and has no cytotoxicity, The present inventors have found that oleic acid or a pharmaceutically acceptable salt thereof is useful as an active ingredient of a composition for the prevention and treatment of muscular dystrophy by confirming that it inhibits muscle cell damage and cell death by oxidative stress, The present invention has been completed.

It is an object of the present invention to provide a pharmaceutical composition for preventing or treating muscular atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient or a health food for preventing or improving muscular atrophy .

In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating muscle atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

In addition, the present invention provides a health food for preventing and improving muscular dystrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

Since oleic acid of the present invention is free from cytotoxicity and exhibits a remarkable effect of treating muscular atrophy by inhibiting muscle cell damage and cell death due to oxidative stress, oleic acid or its pharmaceutical composition Acceptable salts can be usefully employed as active ingredients in compositions for preventing and treating muscular atrophy.

FIG. 1 shows the cytotoxicity of oleic acid. FIG.
FIG. 2 shows the effect of oleic acid on muscle cell damage induced by oxidative stress. FIG.

Hereinafter, terms of the present invention will be described.

As used herein, the term "prophylactic " refers to any act that inhibits the onset or delays the onset of the administration of the composition. In the present invention, "improvement" or "treatment" means any action in which administration of the composition improves or alters the symptoms of the disease.

In the present invention, "administration" means providing a predetermined substance to a patient in any suitable manner, and the administration route of the composition of the present invention may be oral or parenteral ≪ / RTI > The composition may also be administered by any device capable of transferring the active agent to the target cell.

Hereinafter, the present invention will be described in detail.

The present invention provides a pharmaceutical composition for preventing or treating muscular atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The oleic acid may be separated from animal fats such as olive oil, canola oil or beef or pork, commercially available ones, or any of those produced by known chemical synthetic methods, and it is a natural product-derived material, It is harmless to human body and has a chemical formula described by the following Chemical Formula 1.

[Chemical Formula 1]

Figure 112015119129519-pat00001

In addition, the oleic acid is a molecular formula as a kind of a monounsaturated fatty acid is a C 17 H 33 COOH, is UPAC Name (9Z) -Octadec-9-enoic acid.

The oleic acid preferably inhibits muscle cell damage or muscle cell death, and the atrophy may be caused by muscle atrophy caused by loss of muscle tissue caused by not using the muscle, muscle atrophy caused by the muscle itself, The muscle atrophy caused by the loss of muscle tissue caused by not using the muscle is called disuse atrophy and muscle atrophy caused by the muscle itself is severe. Myasthenia gravis or dystrophy and muscle atrophy caused by damage to muscular nerves may be caused by spinal musculular amyotrophy, amyotrophic lateral sclerosis or sphinobular muscular atrophy atrophy), but is not limited thereto.

In addition, in a specific example of the present invention, the present inventors confirmed the cytotoxicity of oleic acid after culturing muscle cells, and found that oleic acid was not cytotoxic in muscle cells (see FIG. 1).

In addition, the present inventors confirmed the effect of oleic acid on oxidative stress induced muscle cell damage. As a result, the survival rate of muscle cells was decreased upon treatment with H 2 O 2 , but when oleic acid of the present invention was treated, Confirming that the survival rate of muscle cells was restored (see FIG. 2).

Therefore, oleic acid of the present invention is free from cytotoxicity, and inhibits muscle cell damage and cell death, and exhibits a remarkable effect of treating atrophy. Thus, oleic acid or a pharmaceutically acceptable salt thereof of the present invention is useful as a medicine for prevention and treatment of muscular dystrophy And may be usefully used as an active ingredient of the composition.

The present invention includes oleic acid represented by the formula (1) as well as its pharmaceutically acceptable salts, possible solvates, hydrates, racemates, or stereoisomers thereof which can be prepared therefrom.

The oleic acid represented by formula (1) of the present invention can be used in the form of a pharmaceutically acceptable salt, and as the salt, an acid addition salt formed by a pharmaceutically acceptable free acid is useful. Acid addition salts include those derived from inorganic acids such as hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, and aliphatic mono- and dicarboxylates, phenyl-substituted alkanoates, hydroxyalkanoates, Dioleate, aromatic acid, aliphatic and aromatic sulfonic acids. Such pharmaceutically innocuous salts include, but are not limited to, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate chloride, bromide, Butyrate, caprate, heptanoate, propiolate, oxalate, malonate, succinate, succinate, maleic anhydride, maleic anhydride, , Sebacate, fumarate, maleate, butyne-1,4-dioate, hexane-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, Methoxybenzoate, phthalate, terephthalate, benzene sulfonate, toluene sulfonate, chlorobenzene sulfide Sulfonate, methanesulfonate, propanesulfonate, naphthalene-1-sulphonate, naphthalene-1-sulphonate, , Naphthalene-2-sulfonate or mandelate.

The acid addition salt according to the present invention can be obtained by a conventional method, for example, by dissolving the oleic acid represented by the formula (1) in an excess amount of an acid aqueous solution, and mixing the salt with a water-miscible organic solvent such as methanol, ethanol, acetone or acetonitrile ≪ / RTI > It is also possible to prepare the mixture by evaporating a solvent or an excess acid in the mixture, or by suction filtration of the precipitated salt.

In addition, bases can be used to make pharmaceutically acceptable metal salts. The alkali metal or alkaline earth metal salt is obtained, for example, by dissolving the compound in an excess amount of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and evaporating and drying the filtrate. At this time, it is preferable for the metal salt to produce sodium, potassium or calcium salt. The corresponding silver salt is also obtained by reacting an alkali metal or alkaline earth metal salt with a suitable salt (such as silver nitrate).

When the composition is formulated, it is prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used.

Solid formulations for oral administration include tablets, patients, powders, granules, capsules, troches and the like, which may contain one or more excipients such as starch , Calcium carbonate, sucrose or lactose, or gelatin. In addition to simple excipients, lubricants such as magnesium stearate talc are also used. Liquid preparations for oral administration include suspensions, solutions, emulsions or syrups. Various excipients such as wetting agents, sweeteners, fragrances, preservatives and the like are included in addition to commonly used simple diluents such as water and liquid paraffin. .

Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.

Examples of the non-aqueous solvent and suspending agent include propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like. As a base for suppositories, witepsol, macrogol, tween 61, cacao paper, laurin, glycerol, gelatin and the like can be used.

The composition according to the present invention is administered in a pharmaceutically effective amount. In the present invention, "pharmaceutically effective amount" means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will depend on the type of disease, severity, , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including co-administered drugs, and other factors well known in the medical arts. The composition of the present invention can be administered as an individual therapeutic agent or in combination with other therapeutic agents, and can be administered sequentially or simultaneously with conventional therapeutic agents, and can be administered singly or in multiple doses. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without side effects, which can be easily determined by those skilled in the art.

Specifically, the effective amount of the compound according to the present invention may vary depending on the age, sex, and body weight of the patient. In general, 0.1 mg to 100 mg, preferably 0.5 mg to 10 mg per kg of body weight is administered daily or every other day Or one to three times a day. However, the dosage may be varied depending on the route of administration, the severity of obesity, sex, weight, age, etc. Therefore, the dosage is not limited to the scope of the present invention by any means.

The present invention also provides a health food for preventing and improving muscular dystrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.

The oleic acid inhibits muscle cell damage or muscle cell death, wherein the muscular atrophy is caused by muscle atrophy caused by loss of muscle tissue caused by not using the muscle, muscle atrophy caused by the muscle itself, or damage to the muscle But the present invention is not limited thereto.

Therefore, oleic acid of the present invention exhibits a remarkable effect of treating atrophy with inhibition of muscle cell damage and apoptosis. Therefore, oleic acid or pharmaceutically acceptable salts thereof of the present invention is an effective ingredient of a health food for the prevention and improvement of muscular atrophy Can be usefully used.

There are no particular restrictions on the type of food to which oleic acid is added. Examples of the foods to which the above substances can be added include dairy products including dairy products, meat, sausage, bread, biscuits, rice cakes, chocolate, candies, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, Beverages, alcoholic beverages and vitamin complexes, dairy products, and dairy products, all of which include health functional foods in a conventional sense.

The oleic acid of the present invention can be added directly to the food or can be used together with other food or food ingredients, and can be suitably used according to conventional methods. The amount of the active ingredient to be mixed can be suitably determined according to the intended use (for prevention or improvement). Generally, the amount of the compound in the health functional food may be 0.1 to 90 parts by weight based on the total weight of the food. However, in the case of long-term intake intended for health and hygiene purposes or for the purpose of controlling health, the amount may be less than the above range, and since there is no problem in terms of safety, the active ingredient may be used in an amount exceeding the above range.

When the health food composition according to the present invention is a beverage composition, there are no particular restrictions on other components other than those containing the above-mentioned compounds as essential components in the indicated ratios, and various flavors or natural carbohydrates, ≪ / RTI > Examples of the above-mentioned natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And polysaccharides, for example, conventional sugars such as dextrin, cyclodextrin and the like, and sugar alcohols such as xylitol, sorbitol and erythritol. Natural flavors (tau martin, stevia extracts (e.g., rebaudioside A, glycyrrhizin, etc.) and synthetic flavors (saccharin, aspartame, etc.) can be advantageously used as flavors other than those described above The ratio of the natural carbohydrate is generally about 1 to 20 g, preferably about 5 to 10 g per 100 of the composition of the present invention.

In addition, the health food composition according to the present invention can be used as a nutritional supplement, a vitamin, a mineral (electrolyte), a flavoring agent such as a synthetic flavor agent and a natural flavor agent, a coloring agent and a thickening agent (cheese, chocolate etc.) Alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents used in carbonated drinks and the like. In addition, it may contain natural fruit juice and pulp for the production of fruit juice drinks and vegetable drinks.

These components may be used independently or in combination. The ratio of such additives is not limited, but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the oleic acid of the present invention.

Hereinafter, the present invention will be described in detail with reference to Examples, Experimental Examples and Preparation Examples.

However, the following Examples, Experimental Examples and Preparation Examples are merely illustrative of the present invention, and the content of the present invention is not limited to the following Examples, Experimental Examples and Production Examples.

< Example  1> Cell culture

Cell cultures were cultured in DMEM medium supplemented with 10% fetal bovine serum (FBS) in normal muscle cells (C2C12: myoblast cell line). Specifically, normal skeletal muscle cells were cultured in a 75 cm 2 plastic flask (SPL life science Co., Ltd. Korea) supplemented with 10% FBS, 7.5% NaHCO 3 150 μg / ml, L-glutamine 58.4 μg / ml, and antibiotic / The cells were cultured in serum-free DMEM high medium containing antimycotics (4.4 μl / ml streptomycin 100 μg / ml, 100 units / ml penicillin) at 37 ° C and 5% CO 2 . Cells were maintained in secondary culture once every 2-3 days. Before subculturing, the cells were washed with phosphate buffered saline (PBS, pH 7.4) and then subcultured with 0.25% trypsine-EDTA.

< Experimental Example  1> Identification of cell viability of oleic acid

The effect of oleic acid on cell proliferation was measured using Ez-cytox kit (Daeil Labservice, Seoul, Korea). 2 × 10 4 cells / well of muscle cells (C2C12: myoblast cell line) are cultured in a 96-well plate for 24 hours. Then, remove the culture medium, dilute the sample with 0, 25, and 50 μM concentration, and pre-incubate for 24 hours at 37 ° C and 5% CO 2 in the incubator. After incubation for 1 hour with Ez-cytox kit solution, viable cells were determined by measuring absorbance at 450 nm with ELISA (BioTek, USA).

As a result, as shown in Fig. 1, when the proliferation rate when oleic acid was not treated was 100.00%, it was confirmed that there was no cytotoxicity in muscle cells when treated up to 50 μM concentration (Fig. 1).

< Experimental Example  2> With oxidative stress  Induced Muscle cell  Identification of effect of oleic acid on damage

To determine the effect of oleic acid concentration on cell death induced by H 2 O 2 , muscle cells were divided into 2 × 10 4 cells / well in a 96-well plate. Then, the cells were cultured in an incubator at 37 ° C and 5% CO 2 for 24 hours. Then, the medium is changed to oleic acid at a concentration of 0, 10, 25, and 50 μM, respectively. Adjust the total volume to 200 μl with DMEM medium. And cultured at 37 ° C and 5% CO 2 for 24 hours. H 2 O 2 was added to the culture solution to a total volume of 190 μl at a concentration of 0 mM and 1 mM, and then cultured for another 60 minutes. After incubation, 10 E of EzCytox kit was added, and after 1 hour, absorbance was measured at 595 nm by ELISA (BioTek, USA) to determine its effect.

As a result, as shown in FIG. 2, when H 2 O 2 was not added, muscle cells showed a survival rate of 100%, and it was confirmed that H 2 O 2 treatment decreased the cell survival rate. In addition, it was confirmed that when oleic acid was treated, the survival rate of muscle cells was restored according to the concentration (FIG. 2).

Therefore, it was confirmed that oleic acid significantly restored muscle cell damage to oxidative stress in a concentration-dependent manner.

< Manufacturing example  1> Manufacture of Pharmaceuticals

One. Sanje  Produce

500 ng of oleic acid of the present invention

Lactose 1 g

The above components were mixed and packed in airtight bags to prepare powders.

2. Preparation of tablets

500 ng of oleic acid of the present invention

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, tablets were prepared by tableting according to a conventional method for producing tablets.

3. Preparation of capsules

500 ng of oleic acid of the present invention

Corn starch 100 mg

Lactose 100 mg

Magnesium stearate 2 mg

After mixing the above components, the capsules were filled in gelatin capsules according to the conventional preparation method of capsules.

4. Preparation of injections

500 ng of oleic acid of the present invention

180 mg mannitol

Na2HPO42H2O 26 mg

Distilled water 2974 mg

According to the conventional method for preparing an injectable preparation, an injectable preparation was prepared by incorporating the aforementioned components in the amounts indicated.

< Manufacturing example  2> Manufacture of health food

1. Manufacture of health food

500 ng of oleic acid of the present invention

Vitamin mixture quantity

70 [mu] g of vitamin A acetate

Vitamin E 1.0 mg

0.13 mg of vitamin

0.15 mg of vitamin B2

Vitamin B6 0.5 mg

0.2 [mu] g vitamin B12

Vitamin C 10 mg

Biotin 10 μg

Nicotinic acid amide 1.7 mg

Folic acid 50 mg

Calcium pantothenate 0.5 mg

Mineral mixture quantity

1.75 mg of ferrous sulfate

0.82 mg of zinc oxide

Magnesium carbonate 25.3 mg

Potassium monophosphate 15 mg

Secondary calcium phosphate 55 mg

Potassium citrate 90 mg

Calcium carbonate 100 mg

Magnesium chloride 24.8 mg

Although the composition ratio of the above-mentioned vitamin and mineral mixture is comparatively mixed with a composition suitable for health food as a preferred embodiment, the compounding ratio may be arbitrarily modified, and the above ingredients are mixed according to a conventional method for producing healthy foods , Granules can be prepared and used in the manufacture of health food compositions according to conventional methods.

2. Manufacture of health drinks

500 ng of oleic acid of the present invention

Citric acid 1000 mg

100 g of oligosaccharide

Plum concentrate 2 g

Taurine 1 g

Purified water was added and the entire 900 ml

The above ingredients were mixed according to the usual health drink manufacturing method, and the mixture was stirred and heated at 85 for about 1 hour. The resulting solution was filtered to obtain a sterilized 2-liter container, which was sealed and sterilized, And used for manufacturing.

Although the composition ratio is relatively mixed with the ingredient suitable for the favorite drink, it is also possible to arbitrarily modify the blending ratio according to the regional or national preference such as the demand class, demand country, use purpose, and the like.

Claims (10)

A pharmaceutical composition for preventing or treating muscular atrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
The pharmaceutical composition for preventing or treating muscular atrophy according to claim 1, wherein the oleic acid has a chemical formula represented by the following formula (1): &lt; EMI ID =
[Chemical Formula 1]
Figure 112015119129519-pat00002
.
The pharmaceutical composition for preventing or treating muscular dysfunction according to claim 1, wherein the oleic acid inhibits muscle cell damage or muscle cell death.
The method according to claim 1, wherein the muscular atrophy is a muscle atrophy caused by loss of muscle tissue caused by not using a muscle, atrophy caused by a muscle itself, or muscle atrophy caused by damage to a muscle that dominates the muscle A pharmaceutical composition for the prevention or treatment of obesity.
The pharmaceutical composition for preventing or treating muscular atrophy according to claim 4, wherein the muscle atrophy caused by loss of muscle tissue caused by not using the muscle is disuse atrophy.
[Claim 5] The pharmaceutical composition according to claim 4, wherein the muscle atrophy caused by the muscle itself is myasthenia gravis or dystrophy.
The method according to claim 4, wherein the muscle atrophy caused by damage to the nerve that dominates the muscle is composed of spinal musculular amyotrophy, amyotrophic lateral sclerosis and sphinobular muscular atrophy Wherein the composition is at least one selected from the group consisting of: &lt; RTI ID = 0.0 &gt;
A health food for preventing and improving muscular dystrophy comprising oleic acid or a pharmaceutically acceptable salt thereof as an active ingredient.
The health food for preventing and improving muscular dysfunction according to claim 8, wherein the oleic acid inhibits muscle cell damage or muscle cell death.
9. The method of claim 8, wherein the muscular atrophy is muscle atrophy caused by loss of muscle tissue caused by not using muscle, muscle atrophy caused by muscle itself, or muscle atrophy caused by muscle damage Health food for prevention and improvement of muscular dystrophy.





KR1020150172681A 2015-12-04 2015-12-04 Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient KR101785970B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020150172681A KR101785970B1 (en) 2015-12-04 2015-12-04 Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020150172681A KR101785970B1 (en) 2015-12-04 2015-12-04 Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient

Publications (2)

Publication Number Publication Date
KR20170066092A KR20170066092A (en) 2017-06-14
KR101785970B1 true KR101785970B1 (en) 2017-10-17

Family

ID=59218192

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020150172681A KR101785970B1 (en) 2015-12-04 2015-12-04 Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient

Country Status (1)

Country Link
KR (1) KR101785970B1 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094917A1 (en) 2002-05-13 2003-11-20 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
JP2013526865A (en) 2010-05-13 2013-06-27 ニトロメガ コーポレーション Nitro fatty acids, neuroprotection and / or suppression of cognitive decline
KR101499457B1 (en) * 2013-10-07 2015-03-09 연세대학교 원주산학협력단 Food and pharmaceutical composition for preventing or improving atrophy comprising extract of Oenothera odorata as effective component

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003094917A1 (en) 2002-05-13 2003-11-20 Takata Seiyaku Co., Ltd. Vintoperol-containing medicinal composition for transdermal administration
JP2013526865A (en) 2010-05-13 2013-06-27 ニトロメガ コーポレーション Nitro fatty acids, neuroprotection and / or suppression of cognitive decline
KR101499457B1 (en) * 2013-10-07 2015-03-09 연세대학교 원주산학협력단 Food and pharmaceutical composition for preventing or improving atrophy comprising extract of Oenothera odorata as effective component

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Biotechnology, and Biochemistry, 80(1), (Published online: 2015.08.19.)*

Also Published As

Publication number Publication date
KR20170066092A (en) 2017-06-14

Similar Documents

Publication Publication Date Title
KR101382400B1 (en) Composition comprising Protaetia brevitarsis for preventing and treating Inflammatory Disorder
KR101800632B1 (en) Pharmaceutical composition, food composition or food additives for prevention, improvement or treatment of muscle loss, weakening, and atrophy comprising Enterococcus faecalis, it culture broth or heat killed Enterococcus faecalis as an active ingredient
EP2702996A1 (en) Anemia-ameliorating composition
KR102242668B1 (en) Composition for improving, preventing or treating bone diseases comprising Lactobacillus sakei CVL-001 or culture medium thereof
JP2022079551A (en) Composition for inhibiting myofibrosis
JP2024050702A (en) Composition for preventing or treating obesity or obesity-induced metabolic syndrome, comprising Enterococcus faecalis as an active ingredient
KR20210047594A (en) Compositions for reinforcing skin barrier and improving atopic dermatitis using hydrangenol or phyllodulcin as an active ingredient
KR101735061B1 (en) Composition containing Artemisia annua extract, artemisinin or dihydroartemisinin for preventing or treating obesity
KR101941183B1 (en) Maximowiczia Chinensis Extracts effective component for preventing and treating arthritis And Manufacturing Method of thereof
JP2022110113A (en) Pharmaceutical composition, food composition and food additive for preventing, alleviating or treating muscle loss, weakness and atrophy, containing, as active ingredient, enterococcus faecalis, culture liquid thereof or dead cells thereof
KR101152479B1 (en) Composition comprising defatted green tea seed extract for preventing and treating inflammatory or cancer disease
KR101785970B1 (en) Pharmaceutical composition for the prevention or treatment of muscle loss comprising Oleic acid or pharmaceutically acceptable salts thereof as an active ingredient
KR20200022660A (en) Composition for preventing or treating of fatty liver, hyperlipemia or obesity comprising mixed extracts
KR102379612B1 (en) Composition for preventing and treating osteoporosis comprising extracts of fermented tenebrio molitor larva
KR20150001109A (en) A composition for preventing or treating dementia through multi-target control
KR101751393B1 (en) Pharmaceutical composition for the prevention or treatment of muscle loss comprising linoleic acid or pharmaceutically acceptable salts thereof as an active ingredient
KR101436213B1 (en) Compositions for prevention and/or treatment of obesity comprising extracts of Boehmeria sieboldiana
KR20160094313A (en) Composition for anti-obesity comprising Chaenomelis Fructus extract or its fraction as effective component
KR101753057B1 (en) Pharmaceutical composition for prevention or treatment of cognitive dysfunction or degenerative brain disease
KR20130009685A (en) Composition comprising esculetin for inhibition of bone loss
KR101622032B1 (en) Pharmaceutical composition comprising Cymbidium extract for preventing or treating muscle atrophy
KR102162787B1 (en) A composition for promoting differentiation of myoblast comprising sabinene
KR20140111186A (en) Composition comprising extract of Physalis angulata for inhibiting cell aging
KR101788306B1 (en) Composition comprising Machilin A for treating or preventing endometriosis
KR20240054436A (en) Peptide having sarcopenia improve activity and Composition for improving, protecting or treating sarcopenia comprising thereof

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
E701 Decision to grant or registration of patent right
GRNT Written decision to grant